Document is current
Any future updates will be listed below
-
Authors
Fang, Haizong
You, Peidong
Lin, Shengzhe https://orcid.org/0009-0000-2520-8957
Wu, Yuwei
Lin, Jiajing
Hou, Zelin
Liang, Feihong
Chen, Changgan https://orcid.org/0000-0003-2296-8621
Wang, Zhiyuan
Chen, Linlin
Zhang, Shihan
Chen, Xiaolan
Zhao, Kui https://orcid.org/0000-0001-9077-6838
Lu, Fengchun
Pan, Minggui https://orcid.org/0000-0002-8368-6524
Zhou, Yundong
Yin, Chengliang https://orcid.org/0000-0001-8262-5749
Conde, João https://orcid.org/0000-0001-8422-6792
Huang, Heguang https://orcid.org/0000-0003-2716-5975
- License Information
-
More Information
Article History
Received: 6 August 2024
Accepted: 18 June 2025
First Online: 11 August 2025
Competing interests
: J.C. is a co-founder and shareholder of TargTex S.A. Targeted therapeutics for Glioblastoma Multiforme. J.C. is also a member of the Global Burden Disease (GBD) consortium from Institute for Health Metrics and Evaluation (IHME), University of Washington. Y.P., F. Liang and P.Y. are authors of a provisional patent (202411349874.8, China) based on this paper. The other authors declare no competing interests.
